We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PINPOINT: Gaming Technology for SCD Pain (Pinpoint II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04579926
Recruitment Status : Completed
First Posted : October 8, 2020
Last Update Posted : August 2, 2022
Sponsor:
Collaborators:
National Institute on Minority Health and Health Disparities (NIMHD)
Hilton Publishing Company
Information provided by (Responsible Party):
Klein Buendel, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet programs to assist SCD adolescents with better identification and communication about pain are lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve self-care. Pinpoint is an interactive gaming app that will be tested in a Phase II project to determine whether the app assists SCD teens with improving their communication and identification skills for pain self-report.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Sickle Cell Anemia in Children Sickle Cell Thalassemia Sickle Cell SC Disease Other: Pinpoint app Not Applicable

Detailed Description:
Sickle cell disease (SCD) is the most common inherited blood disorder in the U.S. and disproportionately affects African Americans and Hispanics. Approximately, 1,000 U.S. children are born with SCD annually. SCD results from abnormal hemoglobin and causes red blood cells (RBCs) to become misshaped ("sickle-shaped"). Sickled cells can block the flow of blood in small arteries causing tissue and organ damage and other life-threatening comorbidities. SCD complications can be serious and have a significant impact upon well-being and quality of life. Pain is the hallmark symptom associated with SCD, and is the most common clinical problem seen in children and the number one cause of SCD-related hospital admissions. If left untreated, these painful episodes can result in morbidity and mortality. Accurate assessment of pain specifiers (type, frequency, and intensity of pain) can help with ameliorating pain quickly and effectively. Despite children being accurate self-reporters of their pain, strategies which are effective and engaging to assist with pain identification and communication of pain are lacking. In a Phase I SBIR, the investigator's team examined the feasibility and acceptability of a gamified tablet application (Pinpoint) intended to encourage teens to talk about and assess their SCD pain. The Phase I specific aims were : (1) work with an Expert Advisory Board (EAB) of experts to develop a new pain assessment tool (PAT) to engage adolescent SCD patients, improve pain specification by patients, and improve pain management by clinicians; (2) conduct cognitive interviews and focus groups with 13-17 year old SCD patients to guide and refine development of app content, design, and aesthetics to fully develop a functioning prototype; (3) conduct usability testing with 13-17 year old SCD patients to assess functionality, navigation, and satisfaction; (4) conduct cognitive interviews with medical providers to provide input on app content, perceived barriers to use, and its potential for clinical use and integration to inform future implementation; and (5) develop a specifications document to outline the Phase II development plan. Deliverables were met and feasibility was confirmed by the EAB. The proposed Phase II project will (1) develop a fully programmed, interactive Pinpoint app consisting of modules to address pain identification and communication; (2) conduct usability testing of Pinpoint to evaluate the user interface, ease of use, and perceived barriers in order to optimize the app prior to large scale evaluation (n=14); and (3) test the full app with 13-17 year olds with SCD (n=100) using a randomized step wedge design to evaluate changes in (a) knowledge acquisition for communicating about pain and types of pain; (b) the Pain Assessment; (c) SCD general knowledge and self-efficacy; (d) family cohesion; and (e) app usage. Overall, the proposed project has the potential to significantly impact the health of SCD teens by providing important skill acquisition for communicating about and identifying pain. This project is innovative and timely. Pinpoint will be the first app to identify and translate specific pain types for SCD into a gamified app using applied gamification principles.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Randomized step wedge design with multiple baselines
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Phase II
Actual Study Start Date : September 19, 2018
Actual Primary Completion Date : June 30, 2022
Actual Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Pinpoint App
Tablet and smartphone application.
 Other: Pinpoint app
Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Sickle Cell Disease (SCD) Knowledge Acquisition [ Time Frame: baseline ]
    Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with an Expert Advisory Board (EAB). Psychometric properties will be evaluated using a 3-step scale development process: (1)domain identification and item generation; (2)content expert validation, and (3)pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.

  2. Sickle Cell Disease (SCD) Knowledge Acquisition [ Time Frame: 4-weeks ]
    Communicating about pain and SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1) domain identification and item generation; (2) content expert validation, and (3) pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.

  3. Sickle Cell Disease (SCD) Knowledge Acquisition [ Time Frame: 8-weeks ]
    Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1)domain identification and item generation; (2)content expert validation, and (3)pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.

  4. Sickle Cell Disease (SCD) Knowledge Acquisition [ Time Frame: 12-weeks ]
    Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1) domain identification and item generation; (2) content expert validation, and (3) pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale developmen

  5. Sickle Cell Disease (SCD) Knowledge Acquisition [ Time Frame: 16-weeks ]
    Communicating about pain & SCD pain knowledge: The primary outcome measure will be developed with the study's EAB. Psychometric properties will be evaluated using a 3-step scale development process: (1)domain identification and item generation; (2)content expert validation, and (3)pilot test. The investigative team will generate items using a sorting process that encompasses themes/construct elements noted in the communication and pain identification literature (Step 1). Items will then be subjected to expert validation by the expert advisory board (Step 2), The Lawshe's Content Validity Ratio (CVR) will assess the content expert judgment; a minimum CVR value of 0.49 will be required for retention in the scale. For Step 3, usability testers will be asked to complete the measure to guide initial psychometric evidence and allow for revision of the instrument prior to study launch. Reporting of internal consistency reliability is a necessary part of scale development.


Secondary Outcome Measures :
  1. PROMIS® (Patient-Reported Outcomes Measurement Information System) [ Time Frame: baseline ]
    subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept

  2. PROMIS® (Patient-Reported Outcomes Measurement Information System) [ Time Frame: 4-weeks ]
    subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept

  3. PROMIS® (Patient-Reported Outcomes Measurement Information System) [ Time Frame: 8-weeks ]
    subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept

  4. PROMIS® (Patient-Reported Outcomes Measurement Information System) [ Time Frame: 12-weeks ]
    subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept

  5. PROMIS® (Patient-Reported Outcomes Measurement Information System) [ Time Frame: 16-weeks ]
    subset of PROMIS measures: The PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of self-report measures that evaluates physical, mental, and social health in adults and children living with or without chronic conditions. The following PROMIS measures will be administered: Family Relationships, Physical Activity, Physical Stress Experiences, Strength Impact, Pain Behavior, Pain Quality- Sensory, Pain Quality-Affective Pain Interference, Psychological Stress Experiences, and Peer Relationships domains. PROMIS measures are scored on the T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. High scores mean more of the concept being measured. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. This could be a desirable or undesirable outcome, depending upon the concept

  6. SCD Knowledge Quiz [ Time Frame: baseline ]
    SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.

  7. SCD Knowledge Quiz [ Time Frame: 4-weeks ]
    SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.

  8. SCD Knowledge Quiz [ Time Frame: 8-weeks ]
    SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.

  9. SCD Knowledge Quiz [ Time Frame: 12-weeks ]
    SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.

  10. SCD Knowledge Quiz [ Time Frame: 16-weeks ]
    SCD knowledge: The SCD Knowledge Quiz is a reliable 10-item measure developed from the Stepping Up to Adult Care Program. Content areas covered are SCD etiology, clinical manifestations, and medical management. Total scores are calculated by summing all items. Higher scores indicate better knowledge of SCD and its treatment.

  11. SCD Transition Knowledge Questionnaire [ Time Frame: baseline ]
    SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.

  12. SCD Transition Knowledge Questionnaire [ Time Frame: 4-weeks ]
    SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.

  13. SCD Transition Knowledge Questionnaire [ Time Frame: 8-weeks ]
    SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.

  14. SCD Transition Knowledge Questionnaire [ Time Frame: 12-weeks ]
    SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.

  15. SCD Transition Knowledge Questionnaire [ Time Frame: 16-weeks ]
    SCD knowledge: The SCD Transition Knowledge Questionnaire is a 25-item measure that assesses SCD knowledge relevant to preparation for transition to adult services. It is designed to assess knowledge in 7 areas: (1) pathophysiology, (2) genetics, (3) physical symptoms, (4) treatment, (5) self-care, (6) psychosocial and developmental issues, and (7) health care delivery. Higher scores indicate better knowledge of SCD and its treatment.

  16. Sickle Cell Self-efficacy Scale [ Time Frame: baseline ]
    SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.

  17. Sickle Cell Self-efficacy Scale [ Time Frame: 4-weeks ]
    SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.

  18. Sickle Cell Self-efficacy Scale [ Time Frame: 8-weeks ]
    SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.

  19. Sickle Cell Self-efficacy Scale [ Time Frame: 12-weeks ]
    SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.

  20. Sickle Cell Self-efficacy Scale [ Time Frame: 16-weeks ]
    SCD self-efficacy: This instrument, used to assess self-efficacy in adolescents with SCD, is comprised of 9 questions measuring participants' perceptions of their ability to function on a day-to-day basis and to manage SCD symptoms (e.g., pain). The instrument is reliable and valid for assessing adolescents' self-efficacy for engaging successfully in day-to-day activities despite having SCD. Responses from individual items are summed to give an overall score, with higher scores indicating greater self-efficacy.

  21. Adolescent Patient-Provider Interaction Scale [ Time Frame: baseline ]
    Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.

  22. Adolescent Patient-Provider Interaction Scale [ Time Frame: 4-weeks ]
    Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.

  23. Adolescent Patient-Provider Interaction Scale [ Time Frame: 8-weeks ]
    Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.

  24. Adolescent Patient-Provider Interaction Scale [ Time Frame: 12-weeks ]
    Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.

  25. Adolescent Patient-Provider Interaction Scale [ Time Frame: 16-weeks ]
    Adolescent patient-provider communication: This 9-item instrument is designed to assess adolescent patient-provider communication and empowerment. Total scores are obtained by summing the Likert-item responses for each question. One item is reverse coded. Higher scores represent better interactions.

  26. Family Cohesion scale from the Child Health Questionnaire (CHQ) [ Time Frame: baseline ]
    Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.

  27. Family Cohesion scale from the Child Health Questionnaire (CHQ) [ Time Frame: 4-weeks ]
    Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.

  28. Family Cohesion scale from the Child Health Questionnaire (CHQ) [ Time Frame: 8-weeks ]
    Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.

  29. Family Cohesion scale from the Child Health Questionnaire (CHQ) [ Time Frame: 12-weeks ]
    Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.

  30. Family Cohesion scale from the Child Health Questionnaire (CHQ) [ Time Frame: 16-weeks ]
    Family communication: Family cohesion will be assessed by the single item Family Cohesion scale ("In general, how would you rate your family's ability to get along with one another?") from the Child Health Questionnaire (CHQ), a pediatric QOL survey that has been normed for children age 5-18 years including those with chronic diseases. The option response is on a 5-point Likert scale. Th score is transformed to a 0 -100 scale, with a mean of 50 and standard deviation of 10. Higher scores better functioning.

  31. System Usability Scale (SUS) [ Time Frame: 16-weeks ]
    Technology acceptability: The System Usability Scale (SUS) is a reliable tool for measuring the usability of technologies. It consists of a 10-item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking. Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be 13-17 years of age
  • Be diagnosed with sickle cell disease
  • Able to read and speak English
  • Able to assent to participate

Exclusion Criteria:

  • Not 13-17 years of age
  • Not diagnosed with sickle cell disease
  • Unable to read and speak English
  • Unable to assent to participate
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04579926


Locations
Layout table for location information
United States, Colorado
Klein Buendel, Inc.
Golden, Colorado, United States, 80401
United States, Indiana
Hilton Publishing Company
Munster, Indiana, United States, 463213963
Sponsors and Collaborators
Klein Buendel, Inc.
National Institute on Minority Health and Health Disparities (NIMHD)
Hilton Publishing Company
Investigators
Layout table for investigator information
Principal Investigator: Valerie Myers, PhD Klein Buendel, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Klein Buendel, Inc.
ClinicalTrials.gov Identifier: NCT04579926    
Other Study ID Numbers: 322
R44MD010746-02 ( U.S. NIH Grant/Contract )
First Posted: October 8, 2020    Key Record Dates
Last Update Posted: August 2, 2022
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Thalassemia
Hemoglobin SC Disease
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
 Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn